Navigation Links
Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
Date:4/21/2011

ce President, R&D of Marinus. "We are pleased that the INTRuST Consortium is conducting this trial and await the results expected in 2012".

About Ganaxolone

Ganaxolone is a synthetic neurosteroid and a derivative of the naturally occurring neuromodulator, allopregnanolone.  Ganaxolone has been administered to more than 950 healthy adult volunteers and patients in Phase 1 and Phase 2 studies. Completed Phase II epilepsy studies have generated data supportive of the efficacy and safety of ganaxolone in the treatment of both children and adults suffering from refractory epilepsy (patients who continue to have seizures despite taking multiple anticonvulsant drugs). Scientific research has suggested that ganaxolone therapy may be useful in the treatment of several other central nervous system disorders including posttraumatic stress disorder (PTSD) and Fragile-X syndrome (FXS). Ganaxolone is being developed as a first in class treatment in epilepsy, PTSD and FXS.

Marinus has successfully developed several proprietary and novel patented formulations of ganaxolone.

About Posttraumatic Stress Disorder (PTSD)

PTSD is a severe anxiety disorder that can develop after exposure to a traumatic event, overwhelming the individual's ability to cope. As an effect of psychological trauma, PTSD is less frequent and more enduring than the more commonly seen acute stress response.

Diagnostic symptoms for PTSD include re-experiencing the original trauma(s) through flashbacks or nightmares, avoidance of stimuli associated with the trauma, and increased arousal – such as difficulty falling or staying asleep, anger and hyper-vigilance. PTSD symptoms cause significant impairment in social, occupational or other important areas of functioning.

Lifetime prevalence is at least 1% and may be as high as 15% in the U.S. population. A national comorbidity survey conducted in the early 1990s found that women are twice as l
'/>"/>

SOURCE Marinus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marinus Pharmaceuticals Issued Patent for Ganaxolone
2. Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Company, Inc. (NYSE: LCI ) today announced that ... Annual Growth Conference on Wednesday, August 12, 2015, at ... A webcast of the presentation will be ... visit the web site at least 10 minutes prior ... and install any necessary software.  The presentation will be ...
(Date:7/30/2015)... -- Flexpoint Ford, a private equity firm focused on ... it has entered into a partnership with Alan ... Kastle Therapeutics, LLC (Kastle).  The new company, headquartered in ... developing and commercializing pharmaceuticals targeted toward diseases with high ... already approved for marketing, as well as clinical assets ...
(Date:7/30/2015)... 30, 2015   HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are ... announced total revenue of $73.6 million for the ... million for the quarter ended June 30, 2014. ... million, or nine percentage points, during the three ...
Breaking Medicine Technology:Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 5HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 6HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 7HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 8HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 9HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 10HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 11HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 12HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 13HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 14
(Date:7/30/2015)... , ... July 30, 2015 , ... ... has worked to protect victims in San Diego, California’s Gaslamp Quarter Plaza for ... by Gaslamp Quarter Plaza actively monitor the area for any suspicious activity. These ...
(Date:7/30/2015)... , ... July 30, 2015 , ... Google recently announced ... upcoming dedicated web site. As discussed in a June 8, 2015 article published by ... reported so far have been caused by its computer-driven cars, which such industry players ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... throughout Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. ... Palliative Care Administrator. Dr. Demoratz is a strong proponent of early access to ...
(Date:7/30/2015)... ... ... The need for accessibility is never greater than when we find ourselves ... as visiting friends and family during these critical moments, hospitals around the Pennsylvania region ... by ChargeItSpot , a Philadelphia-based startup that recently secured a $4M Series A ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... ... Florida’s (UCF) College of Medicine as Assistant Professor of Plastic Surgery. This is ... Dr. Clevens has worked closely with the university, developing a strong presence and a ...
Breaking Medicine News(10 mins):Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3
... a move much appreciated, the US Consumer Product Safety Commission ... under the name BABYBJ'RN? Feeding Spoons. , The company ... move was taken in response to consumer feedback regarding the ... use, the tips of the spoon were observed to soften ...
... a new technique to rapidly detect and precisely ... treatments usually required. ,The technique, called desorption ... create a new class of fast, accurate detectors ... security, said R. Graham Cooks, the Henry Bohn ...
... as he checked himself into a treatment centre near his ... Elena Fondacaro, his manager: "Verne was in rehab and now ... illness that comes and goes ... and Verne realised he ... he's determined to maintain his sobriety." ,In ...
... going cross-eyed even though his optician has reassured him that he ... taking up wearing sunglasses to have his eyes covered all the ... But I can see it when I look in the mirror ... said I should put then on so that people don't have ...
... pressure may seem like something that only adults get, ... children can develop it too -- and just as ... risks to children's hearts, brains and lives. ... pressure, surgery is the best option for those with ...
... may be another reason for pregnant and nursing women to ... vegetables like broccoli and cabbage// – it could help protect ... life. ,A new study by scientists from ... laboratory mice, found that supplements of a key phytochemical found ...
Cached Medicine News:Health News:New Technique to Identify Bacteria for Food Safety 2Health News:New Technique to Identify Bacteria for Food Safety 3Health News:Surgery, the Best Option for Kids With High Blood Pressure 2Health News:Surgery, the Best Option for Kids With High Blood Pressure 3Health News:Mother’s Diet During Pregnancy Could Prevent Cancer in Childre 2Health News:Mother’s Diet During Pregnancy Could Prevent Cancer in Childre 3
... and best value in high performance electronic ... ultra lightweight design reduce hand fatigue and ... lever tip ejector , Color coding for ... or for greater performance use Hamilton AdvanTip ...
... The Finnpipette BioControl multichannel ... features as the single ... handle fits allseven multichannel ... tip cone modules. Both ...
... Pipette is ideal for all liquid handling ... ergonomically-placed operating buttons, and various dispensing techniques ... diluting make this a lab favorite. It ... manual pipette without any adverse effects on ...
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
Medicine Products: